Barbara Nóra Balogh

Dr. Barbara Nóra Balogh

Pharmaceutical Technology, University of Debrecen, Faculty of Pharmacy, Debrecen, Hajdú-Bihar, Hungary
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2024 in Gels
Verified
Journal Article
Open access
PDF file
BBBarbara Nóra Balogh
Barbara Nóra Balogh
ÁPÁgota Pető
Ágota Pető
Adam HaimhofferAdam Haimhoffer
Adam Haimhoffer
DSDavid Sinka
David Sinka
DKDóra Kósa
Dóra Kósa
Dr Bácskay Katalin IldikóDr Bácskay Katalin Ildikó
Dr Bácskay Katalin Ildikó
Psoriasis is an immune-mediated skin condition. There are many therapeutic options for its treatment; however, none of them is completely effective. Tapinarof is a promising new active substance; it was recently approved by the FDA for the treatment of psoriasis. The aim of our study was to prepare topical nanoformulations of the active substance to improve its bioavailability and therapeutic effect. The biocompatibility investigation of the formulations was carried out by MTT assay, and the size distribution of the preparations was investigated by DLS. In parallel, the rheological properties and the texture were examined, and the in vitro release of tapinarof was assessed by the Franz diffusion method. An in vitro wound healing assay was also carried out to study the drug’s properties. Our results show that the preparations were safe on HaCaT cells. The particle size of the formulations was proven to be in the nanoscale range. In the in vitro release studies, nanogel II. showed greater release of the active substance. According to the wound healing assay, incorporation of the drug into nanoformulations increases the antiproliferative and antimigration activity of the drug. Overall, nanoformulations of tapinarof were successfully prepared, and our results suggest that they can be a useful addition to the current therapeutic practice of psoriasis.

1 June 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
BBBarbara Nóra Balogh
Barbara Nóra Balogh
ÁPÁgota Pető
Ágota Pető
Pálma FehérPálma Fehér
Pálma Fehér
Zoltán UjhelyiZoltán Ujhelyi
Zoltán Ujhelyi
Dr Bácskay Katalin IldikóDr Bácskay Katalin Ildikó
Dr Bácskay Katalin Ildikó
Psoriasis is a chronic inflammatory skin disease characterised by increased oxidative stress, the overproliferation of keratinocytes, the accumulation of inflammatory mediators, and skin barrier damage. Although a number of therapeutic options are available, finding long-term treatments that are well-tolerated and patient-friendly treatments remains a challenge. Tapinarof is a new type of aryl hydrocarbon receptor (AhR) modulator that has recently attracted attention as a promising non-steroidal alternative. However, its application may be limited by its poor water solubility and low degree of skin penetration. Nanotechnology-based drug carriers, specially nanogels, offer new opportunities to overcome these limitations by combining the advantages of targeted drug delivery and enhanced skin penetration. Furthermore, nanogel formulations can improve skin hydration and support the restoration of skin barrier function, which are important in the treatment of psoriasis. This review focuses on current and emerging therapeutic approaches, with particular emphasis on the potential of incorporating tapinarof into nanogel formulations as a novel alternative to topical psoriasis treatment.

19 March 2026 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
BBBarbara Nóra Balogh
Barbara Nóra Balogh
ÁKÁgnes Klusóczki
Ágnes Klusóczki
ÁPÁgota Pető
Ágota Pető
PFPálma Fehér
Pálma Fehér
Zoltán UjhelyiZoltán Ujhelyi
Zoltán Ujhelyi
Dr Bácskay Katalin IldikóDr Bácskay Katalin Ildikó
Dr Bácskay Katalin Ildikó
Tapinarof is a novel aryl hydrocarbon receptor (AhR) agonist that has recently been approved for the treatment of psoriasis. Although its clinical efficacy has been proven, in psoriasis, hyperkeratotic plaques and damaged barrier hinder drug penetration from conventional creams and ointments, resulting in poor bioavailability in the deeper layers of the skin. Innovative drug delivery systems can improve targeted action and reduce potential side effects. The primary goal of this study was to evaluate whether tapinarof-loaded nanogels enhance the anti-inflammatory, anti-proliferative, and anti-migratory effects of tapinarof at the cellular level using an in vitro HaCaT-THP-1 co-culture model. Initially, experiments were performed using real-time cell analysis (RTCA), and a concentration of 10 µM was found to be the most effective, showing significant cell proliferation inhibition compared to imiquimod and free tapinarof. To demonstrate cell proliferation and migration during inflammatory conditions, a wound healing assay was performed, which showed inhibited cell migration. Subsequently, the levels of inflammatory cytokines (TNF-α, IFN-γ, IL-17A, IL-23) were analyzed by ELISA, which demonstrated that tapinarof incorporated into nanogels reduced cytokine production more effectively than the drug alone. Quantitative PCR (qPCR) analysis confirmed Imiquimod (IMQ)-induced upregulation of Tnf-α and Ifn-γ, whereas Il-17a and Il-23 did not show measurable transcriptional changes under the experimental conditions. Finally, inhibition of p65 subunit nuclear translocation were observed during NF-κB pathway activation in THP-1 cells by immunofluorescence staining. Overall, our results indicate that nanogel-based delivery systems exhibit enhanced biological effects of tapinarof compared to the free drug in an in vitro psoriasis-like co-culture model, highlighting their potential as therapeutic tools for the treatment of various inflammatory skin diseases.